drugset / Trial / NCT04627038

Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Osteoarthritis

NCT04627038

Phase 2 Completed 202 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is being done to test the safety and efficacy of LY3556050 for the treatment of osteoarthritis pain. This trial is part of the chronic pain master protocol, H0P-MC-CPMP (NCT05986292), which is a protocol to accelerate the development of new treatments for chronic pain.

Timeline

Start
2020-11-12
Primary completion
2021-10-21
Completion
2021-10-21

Drugs

EvaluationDrugModalityDoseRoute
Subject LY3556050 Unknown 600 mg Oral

Indications